What Bencard Allergie does

Bencard Allergie GmbH is a Munich-based pharmaceutical company specializing in allergen-specific immunotherapy (AIT) for the diagnosis and causal treatment of allergies. Founded in 1934 and headquartered in Munich with an Austrian subsidiary in Vienna, it operates as the largest subsidiary of Allergy Therapeutics plc (AIM: AGY), serving the D-A-CH region (Germany, Austria, Switzerland). Its core portfolio comprises prescription-only subcutaneous (SCIT) and sublingual (SLIT) immunotherapy products targeting pollen, house dust mite, insect venom, and other allergies, supplemented by diagnostic tools (prick tests, specific IgE blood tests) and digital patient services including the PollenApp, therapy reminder service, allergy self-test, and physician finder.

The company's technology platform is anchored by proprietary adjuvant systems — MPL (Monophosphoryl-Lipid A) and MCT (Microcrystalline Tyrosin) — licensed from Allergy Therapeutics, which enhance immune response in allergy vaccines. Its flagship commercial product Grassmuno® (Grass MATA MPL), launched in Germany in January 2026, is the first subcutaneous grass pollen immunotherapy approved under the German TAV (Therapieallergene-Verordnung) program, supported by Phase III G306 efficacy data. Pipeline assets include the Polyvac Peanut VLP-based vaccine (Phase I/IIa PROTECT study) and OralVac oral immunotherapies co-developed with Ergomed plc. The business model is built on prescription pharmaceutical sales priced per the official IFA GmbH Lauertaxe medication price list, distributed through a dedicated field sales force (Außendienst) calling on allergists, ENTs, hospitals, and pharmacies across the D-A-CH region, with additional marketing via DAAB online seminars, a DocCheck-gated healthcare professional portal, congress symposia, and the EAACI-sponsored Early Career Research Award.

Name

Bencard Allergie

Legal name

Bencard Allergie GmbH

Website

https://bencard.com

Company type

Private

Founded year

1934

Operating status

Operating

Headcount range

101–250 employees

Short description

Bencard Allergie GmbH is the Munich-based D-A-CH subsidiary of Allergy Therapeutics plc, developing and selling prescription allergen-specific immunotherapy (SCIT/SLIT) products and diagnostics for causal allergy treatment, with proprietary MPL/MCT adjuvant technology.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF), Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

Keywords

• Allergen-specific immunotherapy
• Allergy vaccines
• Allergen diagnostics
• Subcutaneous immunotherapy
• Allergy pharmaceutical products

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain, Infrastructure

Revenue model

1. Prescription Allergy Immunotherapy Products: Bencard Allergie generates revenue primarily through the sale of prescription-only allergy immunotherapy products ( verschreibungspflichtige Produkte) including subcutaneous injections (SCIT) and sublingual treatments. Products are distributed to physicians, clinics, and pharmacies through direct sales force engagement.
2. Diagnostic Products: Sale of diagnostic products including prick test solutions for allergy diagnosis used by allergists and physicians.
3. Service Materials and Educational Resources: Distribution of service materials, educational brochures, and patient resources to healthcare professionals and patients.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Bencard Allergie develops, manufactures, and distributes prescription allergen-specific immunotherapy (AIT) products for the causal treatment of allergies, including subcutaneous (SCIT) and sublingual (SLIT) formulations targeting grass pollen, birch pollen, house dust mites, and insect venom. Its flagship Grassmuno® (Grass MATA MPL) combines modified allergen extracts with proprietary MPL® and MCT adjuvants. The company also provides diagnostic products (skin prick, blood, and provocation tests) and complementary digital patient services such as the PollenApp, allergy self-test, and therapy reminder service, supplied through a field sales force to physicians, clinics, and pharmacies across the D-A-CH region.

Product overview

Bencard Allergie is a pharmaceutical company specializing in allergen immunotherapy (AIT) products and services for allergy treatment. The core portfolio consists of prescription-only allergen immunotherapy products for various allergies (grass pollen, birch pollen, house dust mites, insect venom), including the flagship Grassmuno® (Grass MATA MPL) - a subcutaneous immunotherapy containing MPL® adjuvant and microcrystalline tyrosine. The company also provides a range of digital patient services including the PollenApp with pollen forecasts, an allergy self-test, physician finder, and therapy reminder service. Diagnostic products include prick test solutions, blood tests, and provocation tests. Bencard Allergie operates as part of the Allergy Therapeutics Group with manufacturing at company-owned facilities and distribution through Bencard.

Differentiator

Problem solved

Functional benefit

Brands

• Grassmuno: Subcutaneous grass pollen allergen immunotherapy product with MATA MPL adjuvant system containing Monophosphoryl-Lipid A (MPL) and Microcrystalline Tyrosine (MCT)

Products and services

• Grassmuno® (Grass MATA MPL) Prescription subcutaneous allergen-specific immunotherapy (SCIT) for IgE-mediated grass pollen allergy. Contains grass pollen allergen extracts combined with the proprietary MPL® (Monophosphoryl-Lipid A) and microcrystalline tyrosine (MCT) adjuvant system. Indicated for moderate to severe allergic rhinitis and conjunctivitis in adults, with or without controlled asthma. Administered as a pre-seasonal six-injection course.
• Insektengift-Immuntherapie (Insect Venom Immunotherapy) Prescription allergen-specific immunotherapy for bee and wasp venom allergy. Treatment involves subcutaneous injections of gradually increasing doses over 3-5 years to develop immunological tolerance and reduce the risk of life-threatening anaphylaxis from insect stings. Used by allergists for adult and pediatric patients with confirmed systemic insect venom allergy.
• Allergen-Immuntherapie (AIT) Products for Pollen and House Dust Mite Allergies Portfolio of prescription-only allergen-specific immunotherapy products for grass, birch/tree pollen, and house dust mite allergies, offered in both subcutaneous (SCIT) and sublingual (SLIT) administration formats. Targeted at allergists, ENT physicians, dermatologists, and pediatricians prescribing causal treatment for patients with confirmed IgE-mediated allergies.
• Allergietests (Prick Test, Blood Test, Provocation Test) Diagnostic products and methods for allergy identification, including skin prick tests (Pricktest), specific IgE blood tests, and provocation tests. Used by allergists and physicians in clinical practice to identify allergen sensitivities prior to prescribing allergen-specific immunotherapy.
• PollenApp & Pollenkalender Mobile application and online pollen calendar providing three-day pollen forecasts for the user's region in cooperation with Stiftung Deutscher Polleninformationsdienst. Includes a personal allergy diary and pollen season tracking. Supports patient self-management and therapy adherence.
• Allergie-Selbsttest (Online Allergy Self-Test) Online self-assessment tool that helps users determine whether their symptoms (e.g., itchy eyes, sneezing) are consistent with an allergy. Provides preliminary guidance to encourage specialist consultation. Available free of charge to consumers visiting bencard.com.
• Therapie-Erinnerungsservice (Therapy Reminder Service) Reminder service for patients undergoing Bencard allergen-specific immunotherapy. Sends SMS or email reminders for scheduled treatment appointments using a reference number from the immunotherapy packaging, supporting adherence to multi-year therapy protocols.
• Facharzt-Suche Deutschland (Physician Finder) Online directory tool that helps patients locate allergology-specialized physicians in Germany. Connects allergy patients with prescribing specialists and supports the prescribing physician network.

Quantifiable outcome

• Grass MATA MPL (Grassmuno) showed significant reduction in combined symptom and medication scores versus placebo during grass pollen season in Phase III study G306
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• EAACI (European Academy of Allergy and Clinical Immunology)coreStrategic or Co-development Partner · 1 January 2026EAACI is a leading professional medical society in allergy and clinical immunology. Allergy Therapeutics/Bencard Allergie sponsors the EAACI Early Career Research Award (€30,000 annual grant) to support early career researchers in allergy and immunology. The award is presented at the EAACI Congress and aims to advance research in allergen immunotherapy.
• Ergomed plcminorStrategic or Co-development Partner · 1 December 2017Co-development agreement for clinical development of three OralVac immunotherapy products for allergy treatment.
• DAAB (Deutscher Allergie- und Asthmabund)coreGTM or Marketing PartnerThe German Allergy and Asthma Association is the oldest (since 1897) patient protection organization for allergies, asthma, COPD, urticaria, and neurodermitis. DAAB and Bencard Allergie jointly conduct online seminars for allergy patients, with DAAB experts providing educational content. The partnership supports patient education and awareness.
• Stiftung Deutscher PolleninformationsdienstcoreStrategic or Co-development PartnerThe German Pollen Information Foundation provides pollen forecasts and measurements. Bencard Allergie cooperates with the foundation to provide the PollenApp and pollen calendar, supporting patient management and therapy adherence.
• KulturRaum München e.V.minorOthersMunich cultural organization for families with limited financial resources. Bencard Allergie participates in CSR activities fulfilling Christmas wishes from families supported by KulturRaum.
• Allergy Therapeutics plccoreOthersParent company headquartered in Worthing, UK (AIM:AGY). A research-based pharmaceutical company focused on allergy vaccines. All R&D, manufacturing, and strategic decisions are coordinated through the parent company.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ALK-Abelló: Danish-headquartered global allergy immunotherapy leader (e.g., GRAZAX/ITULAZAX sublingual grass tablets). Directly competes with Bencard's Grassmuno and broader AIT portfolio in Germany and across Europe.
• LETI Pharma: Spanish-headquartered allergy immunotherapy company with European-wide presence; offers SCIT and SLIT products comparable to Bencard's portfolio and competes for share of prescription allergy immunotherapy prescriptions.
• Roxall Medizin: German specialist in allergen extracts and immunotherapy products. Operates in the same regulatory and reimbursement environment (TAV program, AMIS pricing) and serves the same allergist and pharmacy channels in D-A-CH.
• Stallergenes Greer: Global leader in allergen immunotherapy (SCIT and SLIT products, including Oraltek/Bagaza for grass). Directly competes with Bencard in European AIT, serving the same allergists with similar causal-treatment positioning.
• Allergy Therapeutics plc: UK-listed parent company (AIM:AGY). Operates in the same allergen immunotherapy category, develops the MPL/MCT adjuvants, and runs the same product portfolio globally — making it the closest functional and strategic peer, with full operational integration.
• HAL Allergy: European specialist in allergen diagnostics and immunotherapy with strong German-speaking market presence; competes head-to-head with Bencard in SCIT/SLIT and diagnostic products (e.g., prick tests).

Emerging players

• Biomay AG: Vienna-based biotech developing recombinant allergen immunotherapy products. Operates in the same Austrian/German allergy R&D ecosystem and has partnered with major allergy players, making it an emerging comparitor on next-generation AIT technology.
• DBV Technologies: French biotech developing Viaskin epicutaneous immunotherapy for food allergies (including peanut — direct parallel to Bencard's Polyvac Peanut program). Operates in the same food allergy treatment category and targets overlapping specialist prescribers.

Broad incumbents

• Novartis (Palforzia via Stallergenes Greer acquisition): Pharmaceutical major with peanut allergy oral immunotherapy (Palforzia), via its Stallergenes Greer acquisition. Comparable on allergen immunotherapy mechanism and food allergy therapeutic area, though operates from broader pharma base.

Regional players

• Dermapharm Holding SE: German specialty pharmaceutical company with allergy and respiratory products. Operates in adjacent German specialty pharma space, sharing distribution channels (physicians, pharmacies) though not directly competing on allergen immunotherapy core.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bencardallergie

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bencard Allergie